Print this page

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes to treat rare diseases.

RAPIVAB FDA Approved December 2014

RAPIVAB licensed to CSL for the treatment of influenza June 2015

Learn More

To learn more about BioCryst Pharmaceuticals please read the company’s 2014 10K annual report and 2015 proxy.

Read our annual report

Read our proxy

BioCryst's core development programs include avoralstat , BCX7353 and other 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema and BCX4430, a broad spectrum antiviral for hemorrhagic fevers.

May 16, 2015: HAE awareness day.
See BioCryst’s video regarding HAE to learn more

Learn more about BioCryst’s broad spectrum antiviral BCX4430, a potential medical countermeasure for filoviruses.





BioCryst to Present at the Jefferies Autumn 2015 Global Healthcare Conference Nov. 18

Connect to webcast replay & slides